LORETTA NASTOUPIL

TitleAssistant Professor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, Chow VA, Shadman M, Castaneda Puglianini O, Saucier A, Jacobson CA, Armand P, Simmons G. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021 Sep 28; 5(18):3563-3567. PMID: 34474474.
      Citations:    Fields:    
    2. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021 Aug 26; 1-10. PMID: 34435552.
      Citations:    Fields:    
    3. Xie J, Wu A, Liao L, Nastoupil LJ, Du EX, Noman A, Chen L. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving =3 therapy lines in post-CAR-T era. Curr Med Res Opin. 2021 Aug 17; 1-10. PMID: 34344238.
      Citations:    Fields:    
    4. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res. 2021 Aug 11. PMID: 34380640.
      Citations:    Fields:    
    5. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ß/d in relapsed refractory B cell lymphoma. Leuk Lymphoma. 2021 Aug 09; 1-11. PMID: 34365878.
      Citations:    Fields:    
    6. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806. PMID: 34264268.
      Citations:    Fields:    Translation:Humans
    7. Courville J, Nastoupil L, Kaila N, Kelton J, Zhang J, Alcasid A, Nava-Parada P. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs. 2021 Jul; 35(4):459-468. PMID: 34152584.
      Citations:    Fields:    Translation:Humans
    8. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021 Jun 10; 137(23):3272-3276. PMID: 33534891.
      Citations: 5     Fields:    
    9. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 May 04; 1-8. PMID: 33942701.
      Citations:    Fields:    
    10. Nastoupil LJ. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma. Curr Hematol Malig Rep. 2021 02; 16(1):45-51. PMID: 33797691.
      Citations:    Fields:    Translation:HumansAnimals
    11. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2021 Apr 01. PMID: 33792219.
      Citations:    Fields:    
    12. Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021 04 01; 137(13):1832-1835. PMID: 33156925.
      Citations: 2     Fields:    
    13. Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS, Pinnix CC. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol. 2021; 11:648655. PMID: 33842363.
      Citations:    
    14. Munoz J, Follows GA, Nastoupil LJ. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. Target Oncol. 2021 05; 16(3):295-308. PMID: 33687623.
      Citations:    Fields:    
    15. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood. 2021 02 25; 137(8):1124-1129. PMID: 32932518.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    16. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5. PMID: 33965178.
      Citations:    Translation:Humans
    17. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol. 2021 05 01; 96(5):E137-E140. PMID: 33491779.
      Citations:    Fields:    Translation:Humans
    18. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369. PMID: 33480830.
      Citations: 1     Fields:    Translation:Humans
    19. Qiu L, Weitzman SP, Nastoupil LJ, Williams MD, Medeiros LJ, Vega F. Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult. Leuk Lymphoma. 2021 05; 62(5):1234-1238. PMID: 33353436.
      Citations:    Fields:    Translation:Humans
    20. Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1414-1420. PMID: 33309978.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    21. Monga N, Garside J, Gurung B, Quigley J, O'Donovan P, Tapprich C, Nastoupil L, Thieblemont C, Loefgren C. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. Pharmacoecon Open. 2020 Dec; 4(4):575-591. PMID: 32200522.
      Citations:    
    22. Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021 01; 192(2):e38-e42. PMID: 33152104.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    23. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020 12; 26(12):1878-1887. PMID: 33020644.
      Citations: 23     Fields:    Translation:HumansCells
    24. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67. PMID: 32924687.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    25. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020 09 01; 3(9):e2013935. PMID: 32990738.
      Citations:    Fields:    Translation:Humans
    26. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 08 25; 4(16):3943-3951. PMID: 32822484.
      Citations: 9     Fields:    Translation:Humans
    27. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2020 07 30. PMID: 32732355.
      Citations: 6     Fields:    
    28. Lewis KL, Chin CK, Manos K, Casey J, Hamad N, Crawford J, Ho SJ, Issa S, Grigg A, Wood P, Gandhi MK, Do B, Nastoupil L, Hawkes EA, Cheah CY. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. Br J Haematol. 2021 03; 192(6):1049-1053. PMID: 32677095.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    29. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020 07 14; 4(13):2871-2883. PMID: 32589728.
      Citations: 9     Fields:    Translation:Humans
    30. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020 07 14; 4(13):3123-3127. PMID: 32645136.
      Citations: 22     Fields:    Translation:Humans
    31. Furqan F, Watson G, Samaniego F, Fayad LE, Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma. 2020 12; 61(12):2980-2984. PMID: 32650677.
      Citations:    Fields:    Translation:Humans
    32. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma. 2020 12; 61(12):2985-2989. PMID: 32628087.
      Citations:    Fields:    Translation:Humans
    33. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 09 20; 38(27):3119-3128. PMID: 32401634.
      Citations: 52     Fields:    Translation:Humans
    34. Chin CK, Nastoupil LJ. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma. Hematol Oncol Clin North Am. 2020 08; 34(4):743-756. PMID: 32586578.
      Citations:    Fields:    Translation:Humans
    35. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629. PMID: 32239765.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    36. Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ, Oluwole OO, Perales MA, Porter DL, Riedell PA. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246. PMID: 32298807.
      Citations: 24     Fields:    Translation:HumansCellsPHPublic Health
    37. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050. PMID: 32191807.
      Citations: 8     Fields:    Translation:Humans
    38. Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br J Haematol. 2020 05; 189(4):650-660. PMID: 32180219.
      Citations: 5     Fields:    Translation:Humans
    39. Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk. 2020 08; 20(8):533-541. PMID: 32291233.
      Citations: 1     Fields:    Translation:Humans
    40. Gunther JR, Pinnix CC, Glober GR, Christopherson KM, Fang P, Lee HJ, Ahmed S, Steiner RE, Nair R, Strati P, Neelapu SS, Nastoupil LJ, Dabaja BS. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes? EJHaem. 2020 Jul; 1(1):272-276. PMID: 32864660.
      Citations: 1     
    41. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma. 2020 06; 61(6):1380-1387. PMID: 31971032.
      Citations: 1     Fields:    Translation:Humans
    42. Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020 03; 10(3):440-459. PMID: 31915197.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    43. Sunderland AJ, Steiner RE, Al Zahrani M, Pinnix CC, Dabaja BS, Gunther JR, Nastoupil LJ, Jerkeman M, Joske D, Cull G, El-Galaly T, Villa D, Cheah CY. An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Med. 2020 01; 9(2):663-670. PMID: 31808316.
      Citations: 5     Fields:    Translation:Humans
    44. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 11 21; 134(21):1811-1820. PMID: 31558467.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    45. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020 07; 105(7):1907-1913. PMID: 31601688.
      Citations: 3     Fields:    Translation:Humans
    46. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336. PMID: 31533521.
      Citations:    Fields:    Translation:Humans
    47. Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020 01; 61(1):171-175. PMID: 31373240.
      Citations: 2     Fields:    Translation:Humans
    48. Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO, Okosun J. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist. 2019 11; 24(11):e1236-e1250. PMID: 31346132.
      Citations: 8     Fields:    Translation:HumansAnimals
    49. Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leuk Lymphoma. 2019 12; 60(13):3258-3265. PMID: 31234671.
      Citations:    Fields:    Translation:Humans
    50. Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, Nastoupil LJ. Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs. Leuk Lymphoma. 2019 10; 60(10):2356-2364. PMID: 31164024.
      Citations: 2     Fields:    Translation:Humans
    51. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019 06 27; 133(26):2800-2802. PMID: 31101626.
      Citations: 13     Fields:    Translation:Humans
    52. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv. 2019 05 14; 3(9):1356-1367. PMID: 31036721.
      Citations: 1     Fields:    Translation:HumansCells
    53. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 01; 105(1):e26-e28. PMID: 31073068.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    54. Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leuk Lymphoma. 2019 10; 60(10):2432-2440. PMID: 30942648.
      Citations: 1     Fields:    Translation:Humans
    55. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882. PMID: 30919940.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    56. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019 May; 41(5):1546. PMID: 30990235.
      Citations: 1     Fields:    
    57. Andraos T, Ayoub Z, Nastoupil L, Pinnix C, Milgrom S, Gunther J, Ng SP, Fowler N, Neelapu S, Samaniego F, Dabaja B. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):381-389. PMID: 30935940.
      Citations:    Fields:    Translation:Humans
    58. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019 05 23; 133(21):2348-2351. PMID: 30796023.
      Citations: 9     Fields:    Translation:Humans
    59. Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Amini B, Neelapu S, Lee HJ, Westin J, Fowler N, Nastoupil L, Dabaja B. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):447-455. PMID: 30769175.
      Citations: 9     Fields:    Translation:Humans
    60. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109. PMID: 30709431.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    61. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Ann Hematol. 2019 May; 98(5):1169-1176. PMID: 30617643.
      Citations: 2     Fields:    Translation:Humans
    62. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clin Lymphoma Myeloma Leuk. 2019 04; 19(4):244-250. PMID: 30686775.
      Citations: 5     Fields:    Translation:Humans
    63. Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019 02; 184(4):524-535. PMID: 30575016.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    64. Ludmir EB, Gutschenritter T, Pinnix CC, Gunther JR, Nastoupil LJ, Khoury JD, Medeiros LJ, Dabaja BS, Milgrom SA. Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. Onco Targets Ther. 2018; 11:8937-8942. PMID: 30573980.
      Citations:    
    65. Flowers CR, Leonard JP, Nastoupil LJ. Novel immunotherapy approaches to follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):194-199. PMID: 30504310.
      Citations:    Fields:    Translation:Humans
    66. Leonard JP, Nastoupil LJ, Flowers CR. Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):185-188. PMID: 30504308.
      Citations: 1     Fields:    Translation:Humans
    67. Nastoupil LJ, Flowers CR, Leonard JP. Sequencing of therapies in relapsed follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):189-193. PMID: 30504309.
      Citations: 1     Fields:    Translation:Humans
    68. Monga N, Nastoupil L, Garside J, Quigley J, Hudson M, O'Donovan P, Parisi L, Tapprich C, Thieblemont C. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019 Jan; 98(1):175-183. PMID: 30315345.
      Citations: 4     Fields:    Translation:Humans
    69. Nastoupil LJ. Next-generation therapy for follicular lymphoma. Blood. 2018 10 04; 132(14):1465-1467. PMID: 30287467.
      Citations:    Fields:    Translation:Humans
    70. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61. PMID: 30360985.
      Citations: 2     Fields:    Translation:Humans
    71. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018 10 20; 36(30):3043-3054. PMID: 30179565.
      Citations: 55     Fields:    Translation:HumansPHPublic Health
    72. Nastoupil LJ. Point: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma? Oncology (Williston Park). 2018 08 15; 32(8):404-7. PMID: 30153319.
      Citations:    Fields:    Translation:Humans
    73. Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR. Disparities in survival by insurance status in follicular lymphoma. Blood. 2018 09 13; 132(11):1159-1166. PMID: 30042094.
      Citations: 5     Fields:    Translation:Humans
    74. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646. PMID: 30370365.
      Citations: 2     
    75. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019 04; 185(2):334-338. PMID: 29978452.
      Citations: 3     Fields:    Translation:Humans
    76. Nastoupil LJ. Recent insights into large granular lymphocytic leukemia. Clin Adv Hematol Oncol. 2018 Jul; 16(7):469-471. PMID: 30067616.
      Citations:    Fields:    Translation:Humans
    77. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018 Jun 22; 9(48):28897-28902. PMID: 29988979.
      Citations: 6     Fields:    
    78. Loghavi S, Medeiros LJ, Javadi S, Lin P, Khoury JD, Nastoupil L, Hunt KK, Clemens MW, Miranda RN. Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. Aesthet Surg J. 2018 Jun 13; 38(7). PMID: 29635424.
      Citations: 2     Fields:    Translation:Humans
    79. Nastoupil LJ, Prasad V, Flowers CR. The need to assess financial adverse events. Lancet Haematol. 2018 Nov; 5(11):e508-e509. PMID: 29907551.
      Citations: 1     Fields:    Translation:Humans
    80. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343. PMID: 29895624.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    81. Becnel MR, Nastoupil LJ. Follicular Lymphoma: Past, Present, and Future. Curr Treat Options Oncol. 2018 05 24; 19(7):32. PMID: 29796824.
      Citations: 3     Fields:    Translation:HumansAnimals
    82. Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:592-603. PMID: 30231316.
      Citations: 1     Fields:    Translation:Humans
    83. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma. 2018 12; 59(12):2896-2903. PMID: 29697005.
      Citations: 3     Fields:    Translation:Humans
    84. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. 2018 09; 103(9):e416-e418. PMID: 29622656.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    85. Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659. PMID: 29616834.
      Citations: 1     Fields:    Translation:Humans
    86. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):530-540. PMID: 29681481.
      Citations: 6     Fields:    Translation:Humans
    87. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461. PMID: 29538376.
      Citations: 7     Fields:    Translation:Humans
    88. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2018 06; 40(6):1335. PMID: 29851218.
      Citations: 2     Fields:    
    89. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018 05 10; 36(14):1443-1453. PMID: 29461916.
      Citations: 49     Fields:    Translation:Humans
    90. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 06 10; 36(17):1714-1768. PMID: 29442540.
      Citations: 627     Fields:    Translation:Humans
    91. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154. PMID: 29452771.
      Citations: 1     Fields:    Translation:Humans
    92. Becnel M, Flowers CR, Nastoupil LJ. Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation. Ann Lymphoma. 2017 Nov; 1. PMID: 29608198.
      Citations: 2     
    93. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108. PMID: 29196178.
      Citations: 1     Fields:    Translation:Humans
    94. Guidot DM, Switchenko JM, Nastoupil LJ, Koff JL, Blum KA, Maly J, Flowers CR, Cohen JB. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma. 2018 04; 59(4):888-895. PMID: 28797213.
      Citations: 2     Fields:    Translation:Humans
    95. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870. PMID: 28792260.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    96. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol. 2018 09; 182(5):718-723. PMID: 28771675.
      Citations:    Fields:    Translation:Humans
    97. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477. PMID: 28522441.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    98. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844. PMID: 28482717.
      Citations: 2     Fields:    Translation:Humans
    99. Pinnix CC, Andraos TY, Dabaja B, Milgrom S, Smith G, Chihara D, Ng A, Fayad LE, Oki Y, Neelapu S, Westin J, Rodriguez MA, Nastoupil LJ. Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):370-380. PMID: 29114605.
      Citations: 1     
    100. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 05; 22(5):549-553. PMID: 28408615.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    101. Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017 08; 178(3):403-412. PMID: 28382648.
      Citations: 10     Fields:    Translation:Humans
    102. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100. PMID: 28370694.
      Citations: 13     Fields:    Translation:Humans
    103. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270. PMID: 28340281.
      Citations: 3     Fields:    Translation:Humans
    104. Oncale MB, Maymani H, Nastoupil LJ. Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma. Blood Lymphat Cancer. 2017; 7:1-7. PMID: 31360081.
      Citations:    
    105. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758. PMID: 27983760.
      Citations: 20     Fields:    Translation:Humans
    106. Rai A, Nastoupil LJ, Williams JN, Lipscomb J, Ward KC, Howard DH, Lee D, Flowers CR. Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. Leuk Lymphoma. 2017 07; 58(7):1570-1580. PMID: 27830968.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    107. Han X, Jemal A, Hulland E, Simard EP, Nastoupil L, Ward E, Flowers CR. HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):303-311. PMID: 27756777.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    108. Bulka C, Nastoupil LJ, Koff JL, Bernal-Mizrachi L, Ward KC, Williams JN, Bayakly AR, Switchenko JM, Waller LA, Flowers CR. Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence. South Med J. 2016 10; 109(10):606-614. PMID: 27706495.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    109. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9. PMID: 27227654.
      Citations: 7     Fields:    Translation:Humans
    110. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ß2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299. PMID: 27448187.
      Citations: 9     Fields:    Translation:HumansCells
    111. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151. PMID: 27351173.
      Citations: 22     Fields:    Translation:Humans
    112. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016 05; 101(5):531-40. PMID: 27132279.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    113. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol. 2016 Mar; 172(5):724-34. PMID: 26729445.
      Citations: 11     Fields:    Translation:Humans
    114. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8. PMID: 26795083.
      Citations: 3     Fields:    Translation:Humans
    115. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. 2016 11; 175(3):531-533. PMID: 26683805.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    116. Chen Q, Ayer T, Nastoupil LJ, Koff JL, Staton AD, Chhatwal J, Flowers CR. Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016; 57(4):842-51. PMID: 26415108.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    117. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10; 34(2):160-8. PMID: 26628470.
      Citations: 61     Fields:    Translation:Humans
    118. Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep. 2015 Sep; 10(3):244-55. PMID: 26104907.
      Citations: 6     Fields:    Translation:HumansCells
    119. Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. Br J Haematol. 2015 Nov; 171(4):539-46. PMID: 26248505.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    120. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 2015 Nov; 100(11):e454-7. PMID: 26250576.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    121. Flowers CR, Nastoupil LJ. Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. Cancer. 2015 Oct 01; 121(19):3387-9. PMID: 26149195.
      Citations: 1     Fields:    Translation:Humans
    122. Nastoupil LJ, Neelapu SS. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep. 2015 Jul; 17(7):30. PMID: 25986722.
      Citations: 3     Fields:    Translation:HumansCells
    123. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015 May 21; 125(21):3357-9. PMID: 25999447.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    124. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82. PMID: 25863764.
      Citations: 31     Fields:    Translation:Humans
    125. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21. PMID: 25863759.
      Citations: 8     Fields:    Translation:Humans
    126. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. 2015 May; 15(5):531-44. PMID: 25864967.
      Citations: 22     Fields:    Translation:Humans
    127. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2015 Jul; 100(7):e272-4. PMID: 25820332.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    128. Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health. 2015 Mar; 18(2):189-97. PMID: 25773554.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    129. Williams JN, Rai A, Lipscomb J, Koff JL, Nastoupil LJ, Flowers CR. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015 Jun 01; 121(11):1800-8. PMID: 25675909.
      Citations: 15     Fields:    Translation:Humans
    130. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma. 2015 May; 56(5):1295-302. PMID: 25263322.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    131. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8. PMID: 25439689.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    132. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014 Nov; 25(11):2211-2217. PMID: 25193992.
      Citations: 35     Fields:    Translation:Humans
    133. Nastoupil LJ. Routine use of maintenance therapy in follicular lymphoma: the strategy is effective, raising the question, 'what is the most important measure of success in the current era?'. Oncology (Williston Park). 2014 Sep; 28(9):786, 793. PMID: 25224478.
      Citations:    Fields:    Translation:Humans
    134. Nastoupil LJ, Shenoy PJ, Ambinder A, Koff JL, Nooka AK, Waller EK, Langston A, Seward M, Kaufman JL, Bernal-Mizrachi L, King N, Lechowicz MJ, Lonial S, Sinha R, Flowers CR. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma. 2015 Feb; 56(2):383-9. PMID: 24828864.
      Citations: 3     Fields:    Translation:Humans
    135. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84. PMID: 25039868.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    136. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      Citations: 82     Fields:    Translation:Humans
    137. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):460-467.e2. PMID: 25052052.
      Citations: 28     Fields:    Translation:Humans
    138. Flowers CR, Nastoupil LJ. Socioeconomic disparities in lymphoma. Blood. 2014 Jun 05; 123(23):3530-1. PMID: 24904097.
      Citations: 15     Fields:    Translation:Humans
    139. Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014 Jun 15; 120(12):1830-7. PMID: 24668580.
      Citations: 12     Fields:    Translation:Humans
    140. Han X, Jemal A, Flowers CR, Sineshaw H, Nastoupil LJ, Ward E. Insurance status is related to diffuse large B-cell lymphoma survival. Cancer. 2014 Apr 15; 120(8):1220-7. PMID: 24474436.
      Citations: 21     Fields:    Translation:Humans
    141. Nastoupil LJ, Koff JL, Flowers CR. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies. Oncology (Williston Park). 2013 Oct; 27 Suppl 2:8-12. PMID: 25374999.
      Citations:    Fields:    Translation:HumansAnimalsCells
    142. Nastoupil LJ, Sinha R, Flowers CR. The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Rev Anticancer Ther. 2013 Sep; 13(9):1089-108. PMID: 23919536.
      Citations:    Fields:    Translation:Humans
    143. Bulka C, Nastoupil LJ, McClellan W, Ambinder A, Phillips A, Ward K, Bayakly AR, Switchenko JM, Waller L, Flowers CR. Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. Cancer. 2013 Sep 15; 119(18):3309-17. PMID: 23896932.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    144. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):569-77. PMID: 23540349.
      Citations: 17     Fields:    Translation:Humans
    145. Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer. 2013 Apr 15; 119(8):1570-7. PMID: 23341329.
      Citations: 11     Fields:    Translation:Humans
    146. Rose AC, Shenoy PJ, Garrett G, Seward M, Kucuk RA, Doksansky H, Nastoupil LJ, Flowers CR. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2012 Dec; 12(6):393-9. PMID: 23158095.
      Citations: 3     Fields:    Translation:Humans
    147. Nastoupil LJ, Flowers CR. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol. 2012 Dec; 9(12):S85-S92. PMID: 23316119.
      Citations: 2     
    148. Nastoupil L, Sinha R, Hirschey A, Flowers CR. Considerations in the initial management of follicular lymphoma. Community Oncol. 2012 Nov 01; 9(11):S53-S60. PMID: 23544009.
      Citations: 2     
    149. Chen Q, Ayer T, Nastoupil LJ, Seward M, Zhang H, Sinha R, Flowers CR. Initial management strategies for follicular lymphoma. Int J Hematol Oncol. 2012 Oct; 1(1):35-45. PMID: 23476737.
      Citations: 3     
    150. Ambinder AJ, Shenoy PJ, Malik N, Maggioncalda A, Nastoupil LJ, Flowers CR. Exploring risk factors for follicular lymphoma. Adv Hematol. 2012; 2012:626035. PMID: 23028387.
      Citations: 5     
    151. Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW, Ward EM. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1520-30. PMID: 22771484.
      Citations: 28     Fields:    Translation:Humans
    152. Nastoupil LJ, Rose AC, Flowers CR. Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park). 2012 May; 26(5):488-95. PMID: 22730604.
      Citations: 7     Fields:    Translation:Humans
    153. Nastoupil LJ, Sinha R, Flowers CR. Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. Eur Oncol Haematol. 2012 May; 8(2):123-126. PMID: 23805375.
      Citations: 2     
    154. Sinha R, Nastoupil L, Flowers CR. Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer. 2012 Apr 19; 2012(2):87-98. PMID: 23532092.
      Citations: 7     
    155. Flowers CR, Nastoupil LJ, Bernal-Mizrachi L, Rose AC, Sinha R. New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol. 2012 Jan; 2(1):68-73. PMID: 23805376.
      Citations: 2     
    156. Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):498-506. PMID: 21889433.
      Citations: 27     Fields:    Translation:Humans
    157. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.
    158. Management of relapsed chronic lymphocytic leukemia. Community Oncology. 9.
    159. Routine use of maintenance therapy in follicular lymphoma. ONCOLOGY (United States). 28.
    160. Diffuse large B-cell lymphoma. ONCOLOGY (United States). 26.
    161. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Review of Anticancer Therapy. 15:531-544.
    162. Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. Cancer. 121:3387-3389.
    163. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology.
    164. Relations between residential proximity to EPA-designated toxic release sites and diffuse large b-cell lymphoma incidence. Southern Medical Journal. 109:606-614.
    165. Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. Leukemia and Lymphoma. 1-11.
    166. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. British Journal of Haematology.
    167. Considerations in the initial management of follicular lymphoma. Community Oncology. 9.
    168. Management strategies for elderly patients with diffuse large B-Cell lymphoma. European Oncology and Haematology. 8:123-126.
    169. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 101:531-540.
    170. Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. Leukemia and Lymphoma. 57:842-851.
    171. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    172. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. British Journal of Haematology. 171:539-546.
    173. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 100:e454-e457.
    174. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    175. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 16:122-128.
    176. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 100:e272-e274.
    177. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. Journal of Clinical Oncology. 34:160-168.
    178. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.
    NASTOUPIL's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (367)
    Explore
    _
    Co-Authors (95)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _